{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:16:40Z","timestamp":1783117000408,"version":"3.54.6"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2025-02-34"],"award-info":[{"award-number":["320.6750.2025-02-34"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.intimp.2026.116665","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T12:07:20Z","timestamp":1776946040000},"page":"116665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting NBL1\/PI3K\/AKT axis to enhance the chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma"],"prefix":"10.1016","volume":"180","author":[{"given":"Bing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renya","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2026.116665_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"10466","key":"10.1016\/j.intimp.2026.116665_bb0010","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/S0140-6736(24)02226-8","article-title":"Oesophageal cancer","volume":"404","author":"Yang","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"12","key":"10.1016\/j.intimp.2026.116665_bb0015","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1002\/ijc.25517","article-title":"Fifty years of cancer incidence: CI5 I-IX","volume":"127","author":"Parkin","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2026.116665_bb0020","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70376","article-title":"Hypoxia-induced PGK1 expression promotes esophageal squamous cell carcinoma progression via stimulating MYH9-mediated GSK3\u03b2\/\u03b2-catenin signalling","volume":"15","author":"Xu","year":"2025","journal-title":"Clin. Transl. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.116665_bb0025","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/gutjnl-2019-320200","article-title":"Effectiveness of one-time endoscopic screening programme in prevention of upper gastrointestinal cancer in China: a multicentre population-based cohort study","volume":"70","author":"Chen","year":"2021","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.intimp.2026.116665_bb0030","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1053\/j.gastro.2024.11.025","article-title":"Effect of an endoscopy screening on upper gastrointestinal cancer mortality: a community-based multicenter cluster randomized clinical trial","volume":"168","author":"Xia","year":"2025","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.intimp.2026.116665_bb0035","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s43018-025-00918-1","article-title":"Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802)","volume":"6","author":"Bando","year":"2025","journal-title":"Nat. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2026.116665_bb0040","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/pro6.1249","article-title":"Exploration of individualized neoadjuvant therapy model for operable esophageal cancer: a surveillance, epidemiology, and end results database analysis","volume":"8","author":"Zhou","year":"2024","journal-title":"Precis. Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116665_bb0045","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/pro6.1232","article-title":"Current status and prospect of particle therapy for esophageal cancer","volume":"8","author":"Wang","year":"2024","journal-title":"Precis. Radiat. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116665_bb0050","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s12032-023-02137-z","article-title":"RNF149 confers cisplatin resistance in esophageal squamous cell carcinoma via destabilization of PHLPP2 and activating PI3K\/AKT signalling","volume":"40","author":"Zhu","year":"2023","journal-title":"Med. Oncol. (Northwood, London, England)"},{"key":"10.1016\/j.intimp.2026.116665_bb0055","article-title":"Targeting TPX2 to enhance metastasis control and radiosensitivity in esophageal squamous cell carcinoma through PI3K\/AKT pathway modulation","author":"Meng","year":"2025","journal-title":"Iran. J. Biotechnol."},{"key":"10.1016\/j.intimp.2026.116665_bb0060","doi-asserted-by":"crossref","DOI":"10.1177\/15330338241274369","article-title":"LncRNA NONHSAT227443.1 confers esophageal squamous cell carcinoma chemotherapy resistance by activating PI3K\/AKT signaling via targeting MRTFB","volume":"23","author":"Wang","year":"2024","journal-title":"Technol. Cancer Res. Treat."},{"issue":"657","key":"10.1016\/j.intimp.2026.116665_bb0065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj2109","article-title":"Neuroblastoma suppressor of tumorigenicity 1 is a circulating protein associated with progression to end-stage kidney disease in diabetes","volume":"14","author":"Kobayashi","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.intimp.2026.116665_bb0070","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.4049\/jimmunol.160.7.3337","article-title":"Stimulation of murine b lymphocytes induces a DNA exonuclease whose activity on switch-mu DNA is specifically inhibited by other germ-line switch region RNAs","volume":"160","author":"M\u00fcller","year":"1998","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116665_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41389-022-00396-5","article-title":"Neuron-specific enolase promotes stem cell-like characteristics of small-cell lung cancer by downregulating NBL1 and activating the BMP2\/Smad\/ID1 pathway","volume":"11","author":"Lu","year":"2022","journal-title":"Oncogenesis"},{"issue":"8","key":"10.1016\/j.intimp.2026.116665_bb0080","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/CJI.0b013e3182a802cf","article-title":"IL-17A promotes immune cell recruitment in human esophageal cancers and the infiltrating dendritic cells represent a positive prognostic marker for patient survival","volume":"36","author":"Lu","year":"2013","journal-title":"J. Immunother."},{"key":"10.1016\/j.intimp.2026.116665_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115711","article-title":"PLK1 regulating chemoradiotherapy sensitivity of esophageal squamous cell carcinoma through pentose phosphate pathway\/ferroptosis","volume":"168","author":"Zhao","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.intimp.2026.116665_bb0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1756-9966-29-34","article-title":"Phosphatidylinositol 3-kinase inhibitor (LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo","volume":"29","author":"Jiang","year":"2010","journal-title":"J. Exp. Clin. Cancer Res.: CR"},{"issue":"3","key":"10.1016\/j.intimp.2026.116665_bb0095","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.leu.2402824","article-title":"Involvement of PI3K\/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.intimp.2026.116665_bb0100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer","volume":"30","author":"Fresno Vara","year":"2004","journal-title":"Cancer Treat. Rev."},{"issue":"30","key":"10.1016\/j.intimp.2026.116665_bb0105","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1111\/1759-7714.15093","article-title":"MiR-1301-3p promotes invasion and migration and EMT progression in esophageal cancer by downregulating NBL1 expression","volume":"14","author":"Du","year":"2023","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.intimp.2026.116665_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.110229","article-title":"Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor talazoparib combination in BRCA-deficient triple negative breast cancer cells","volume":"91","author":"Guney Eskiler","year":"2022","journal-title":"Cell. Signal."},{"issue":"6","key":"10.1016\/j.intimp.2026.116665_bb0115","article-title":"Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinoma","volume":"6","author":"Yates","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116665_bb0120","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12957-025-03957-1","article-title":"CtDNA methylation profiling reveals NBL1 as a promising biomarker for early ovarian cancer screening","volume":"23","author":"Zhou","year":"2025","journal-title":"World J. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116665_bb0125","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000341396","article-title":"The search for secreted proteins in prostate cancer by the escherichia coli ampicillin secretion trap: expression of NBL1 is highly restricted to the prostate and is related to cancer progression","volume":"80","author":"Hayashi","year":"2013","journal-title":"Pathobiology: J. Immunopathol. Mol. Cell. Biol."},{"issue":"12","key":"10.1016\/j.intimp.2026.116665_bb0130","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2337\/db19-0204","article-title":"Comparison of kidney transcriptomic profiles of early and advanced diabetic nephropathy reveals potential new mechanisms for disease progression","volume":"68","author":"Fan","year":"2019","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.intimp.2026.116665_bb0135","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/s41467-021-22368-w","article-title":"Single cell transcriptional and chromatin accessibility profiling redefine cellular heterogeneity in the adult human kidney","volume":"12","author":"Muto","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.intimp.2026.116665_bb0140","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.2011060627","article-title":"Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes","volume":"23","author":"Niewczas","year":"2012","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"8","key":"10.1016\/j.intimp.2026.116665_bb0145","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.celrep.2016.07.046","article-title":"Structure of gremlin-2 in complex with GDF5 gives insight into DAN-family-mediated BMP antagonism","volume":"16","author":"Nolan","year":"2016","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.intimp.2026.116665_bb0150","first-page":"646","article-title":"Tumor-suppressive activity of n03 gene product in v-src-transformed rat 3Y1 fibroblasts","volume":"54","author":"Ozaki","year":"1994","journal-title":"Cancer Res."},{"issue":"39","key":"10.1016\/j.intimp.2026.116665_bb0155","doi-asserted-by":"crossref","first-page":"19619","DOI":"10.1073\/pnas.1908706116","article-title":"The single-cell transcriptomic landscape of early human diabetic nephropathy","volume":"116","author":"Wilson","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.intimp.2026.116665_bb0160","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41422-023-00918-9","article-title":"The roles and regulatory mechanisms of TGF-\u03b2 and BMP signaling in bone and cartilage development, homeostasis and disease","volume":"34","author":"Wu","year":"2024","journal-title":"Cell Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.116665_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21113888","article-title":"Extracellular BMP antagonists, multifaceted orchestrators in the tumor and its microenvironment","volume":"21","author":"Ouahoud","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.116665_bb0170","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3892\/ijo.2016.3802","article-title":"BMP signaling pathways affect differently migration and invasion of esophageal squamous cancer cells","volume":"50","author":"Hu","year":"2017","journal-title":"Int. J. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116665_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158755","article-title":"Correction: BMP4 signaling is able to induce an epithelial-mesenchymal transition-like phenotype in Barrett\u2019s esophagus and esophageal adenocarcinoma through induction of SNAIL2","volume":"11","author":"Kestens","year":"2016","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.intimp.2026.116665_bb0180","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jcmgh.2023.01.003","article-title":"Inhibition of BMP2 and BMP4 represses Barrett\u2019s esophagus while enhancing the regeneration of squamous epithelium in preclinical models","volume":"15","author":"Correia","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"21","key":"10.1016\/j.intimp.2026.116665_bb0185","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1158\/0008-5472.CAN-17-1411","article-title":"FSTL1 promotes metastasis and chemoresistance in esophageal squamous cell carcinoma through NF\u03baB-BMP signaling cross-talk","volume":"77","author":"Lau","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116665_bb0190","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s12967-022-03720-0","article-title":"Irradiation-induced exosomal HMGB1 to confer radioresistance via the PI3K\/AKT\/FOXO3A signaling pathway in ESCC","volume":"20","author":"Du","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116665_bb0195","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.canlet.2019.10.004","article-title":"SOX9\/miR-203a axis drives PI3K\/AKT signaling to promote esophageal cancer progression","volume":"468","author":"Wang","year":"2020","journal-title":"Cancer Lett."},{"issue":"4\u20135","key":"10.1016\/j.intimp.2026.116665_bb0200","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1006\/pulp.1995.1026","article-title":"The role of sensory neuropeptides in airway hyperresponsiveness","volume":"8","author":"Baraniuk","year":"1995","journal-title":"Pulm. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116665_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.782065","article-title":"LY294002 is a promising inhibitor to overcome sorafenib resistance in FLT3-ITD mutant AML cells by interfering with PI3K\/Akt signaling pathway","volume":"11","author":"Huang","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116665_bb0210","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3892\/ijo.2016.3804","article-title":"PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells","volume":"50","author":"Wang","year":"2017","journal-title":"Int. J. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116665_bb0215","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/j.1349-7006.2008.00891.x","article-title":"Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy","volume":"99","author":"Kong","year":"2008","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.intimp.2026.116665_bb0220","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"issue":"20","key":"10.1016\/j.intimp.2026.116665_bb0225","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116665_bb0230","article-title":"A systematic CRISPR screen reveals an NBL1-mediated Jak\/Stat3 crosstalk to promote ovarian cancer metastasis","volume":"13","author":"Qi","year":"2026","journal-title":"Genes Dis."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926005102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926005102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:23:30Z","timestamp":1783113810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926005102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":46,"alternative-id":["S1567576926005102"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116665","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting NBL1\/PI3K\/AKT axis to enhance the chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116665"}}